The 340B drug discount program, designed to provide low-cost drugs to safety net providers, is broken due to lack of transparency, confusion with other programs, and lack of collaboration. This has led to billions of dollars in duplicate discounts and non-compliant claims. To address these issues, stakeholders need to prioritize transparency, ensure equal access to data, and reduce disputes over discount claims. Collaboration and trust between drug manufacturers, Covered Entities, and state Medicaid agencies are essential for improving the program and achieving its intended goal of providing affordable pharmaceuticals to consumers.
Source link
How Covered Entities and Pharma Companies Can Better Collaborate on Drug Discount Programs
